The impact of missing data and unmeasured confounding in External Comparator studies can lead to biased study results. In this article, IQVIA’s Gerd Rippin, other IQVIANs and EMA experts demonstrate differences in some methodological approaches and derive recommendations for the most appropriate statistical approach to reduce any induced bias. https://bit.ly/4j4j90G
IQVIA
Hospitals and Health Care
Durham, North Carolina 2,164,917 followers
Accelerate innovation for a healthier world.
About us
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
- Website
-
https://www.iqvia.com/
External link for IQVIA
- Industry
- Hospitals and Health Care
- Company size
- 10,001+ employees
- Headquarters
- Durham, North Carolina
- Type
- Public Company
- Specialties
- Technology, Consulting, and Clinical Development
Locations
-
Primary
Get directions
2400 Ellis Rd
Durham, North Carolina 27703, US
Employees at IQVIA
Updates
-
Ready to be part of something new in 2025? Join our Global Talent Network for job alerts and exclusive insights into life at IQVIA: https://bit.ly/40iCbsL #WeAreIQVIA
-
-
The Medicare Part D redesign will significantly increase #patientsupport demands in January. Now is the time to evaluate call volumes, optimize capacity, and train your staff. Learn how to respond from #IQVIA patient support experts Nancy McGee, JD, MPH, DrPH, Jennifer Millard, and James Brown in their recent article, "How Patient Support Can Ease Transitions to the Part D Redesign in 2025." Read more. https://bit.ly/4iWoczR
-
The Informa #PatientSupport Services Congress emphasized the importance of dismantling silos between innovation and compliance. In their latest blog, #IQVIA experts Jara Soltero, Brian Lovinguth, and Annie Bhattacharjee share the top five insights from the congress and discuss proactive risk management strategies. Learn how to align innovative practices with regulatory requirements to build patient trust. https://bit.ly/41SnH3V
-
-
Looking for industry-leading #RealWorldEvidence perspectives? Access #IQVIA's Real World Evidence Library for expert content to help you meet stakeholder needs with confidence and get real results. https://bit.ly/3Dq0rAe
-
'Tis the season to be inspired! Explore Alex Moffatt’s journey from a week-long program to IQVIA’s management track. Limitless growth awaits at IQVIA: https://bit.ly/4fyuWkT #WeAreIQVIA
-
-
As the use of digital health technologies (DHTs) increases in clinical practice, so does the need for established regulatory and assessment frameworks and reimbursement pathways. This article by IQVIA’s Xenia Radu-Sitavu, PhD and Catia Modesto da Silva explores the new Evidence Standards Framework (ESF) published by the National Institute for Health and Care Excellence (NICE) in the UK and its goals to ensure the clinical effectiveness and consistent assessment of DHTs across the National Health System (NHS). https://bit.ly/401f85A
-
-
The new HTAR will come into effect early 2025 and Joint Scientific Consultation (JSC) will be part of this process. During the pilot phase it became clear that companies who carefully consider the need for JSC and meticulously plan for scientific advice will be able to better meet Joint Clinical Assessment (JCA) requirements and accelerate EU patient access. Our Insight Guide outlines how to get the most value from scientific consultation with HTA bodies and important information to understand before applying. https://bit.ly/3Do56m9
-
Affiliated pages
Similar pages
Browse jobs
Stock
IQV
NYSE
20 minutes delay
$194.63
-0.495 (-0.254%)
- Open
- 195.885
- Low
- 194.22
- High
- 197.29
Data from Refinitiv
See more info on